BERGUI, Mauro
BERGUI, Mauro
NEUROSCIENZE "RITA LEVI MONTALCINI"
A 4-year multicenter follow-up of neutralizing anti-interferon antibodies in ms patients treated with high dose (375 mcg) interferon beta-1b
2006-01-01 A. TAVELLA; A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; B. FERRERO; A. ROVERA; G. CONTESSA; M. BERGUI; E. VERSINO; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP
A comparison of fully automatic and semi-manual contouring software for quantitative magnetic resonance imaging of lesion load in multiple sclerosis
2005-01-01 E. Festa; P. Barbero; A. Pipieri; M. Bergui; A. Boghi; G. Bradac; L. Giordano; L. Durelli
CEREBELLUM INTRINSIC CONNECTIVITY IN EATING DISORDERS
2012-01-01 F. D’AGATA, P. CAROPPO, L. LAVAGNINO, M. CAGLIO, A. SPALATRO, C. SETTANTA, M. CORIASCO, F. FERRIO, M. BERGUI, F. AMIANTO, S. FASSINO, L. PINESSI, P. MORTARA
Correlation of anti-interferon beta neutralising antobodies with clinical response and mri activity in the INCOMIN (independent comparison of interferon) trial.
2003-01-01 P. BARBERO; E. VERDUN; M. CLERICO; A. PIPIERI; A. RICCI; M. BERGUI; E. VERSINO; G. ANTONELLI; M. ZAFFARONI; A. GHEZZI; E. MONTANARI; L. DURELLI; AND INCOMIN STUDY GROUP
Differences in primary motor cortex identification by BOLD fMRI in patients with AVMs and gliomas
2003-01-01 M. Bergui; M. Bregu; A. Boghi; G. B. Bradac
Different pathogenesis of thalidomide neuropathy in multiple myeloma.
2002-01-01 G. ISOARDO; D. COCITO; P. BARBERO; M. BERGUI; P. CIARAMITARO; A. BERTOLA; M. BOCCADORO; B. BERGAMASCO; L. DURELLI
Different pathogenesis of thalidomide neuropathy in multiple myeloma.
2002-01-01 G. ISOARDO; D. COCITO; P. BARBERO; M. BERGUI; P. CIARAMITARO; A. BERTOLA; M. BOCCADORO; B. BERGAMASCO; L. DURELLI
Diffusion Tensor and Voxel Based Morphometry study in patients with amyotrophic lateral sclerosis
2012-01-01 Paola Caroppo, Federico D’Agata, Maria Federica Ferrio, Mario Coriasco, Andrea Calvo, Adriano Chiò, Dorico Righi, Paolo Mortara, Gianni Boris Bradac, Mauro Bergui
Every-other-day interferon beta-1b compared with once weekly interferon beta 1-a in ms. further analysis of treatment effect on mri activity and neutralizing antibodies (nabs) in the INCOMIN trial
2004-01-01 P. BARBERO; M. BERGUI; A. RICCI; E. VERSINO; A. PIPIERI; E. VERDUN; M. CLERICO; L. GIORDANO; A. CUCCI; L. DURELLI; INCOMIN STUDY GROUP
Every-other-day interferon beta-1b compared with once-weekly interferon beta-1a in MS. Further analysis of treatment effect on MR1 activity and neutralising antibodies (NAbs) in the INCOMIN Trial
2004-01-01 P. Barbero; A. Ricci; M. Bergui; E. Verdun; E. Versino; E. Montanari; A. Ghezzi; M. Zaffaroni; L. Durelli
Focal gray matter decrease in the cerebral pain network of migraine patients
2006-01-01 Valfre' W; Rainero I; Bergui M; Bradac GB; Gentile S; Ferrero M; Rubino E; Vaula G; Pinessi L
High dose interferon beta-1b in aggressive Multiple Sclerosis. tolerability, clinical and mri results after one year of treatment
2006-01-01 A. PIPIERI; P. BARBERO; M. BERGUI; E. VERSINO; M. CLERICO; L. GIORDANO; L. DELFICO; G. CONTESSA; A.M. CUCCI; E. VERDUN; I. PESCI; L. MANNESCHI; E. CARTECHINI; E. PUCCI; G. GIULIANI; E. MONTANARI; L. DURELLI
High-dose interferon beta-1b (500 mcg every-other-day, subcutaneously) treatment in RR MS patients. Safety and MRI results of 1-year follow-up
2005-01-01 P. Barbero; A. Pipieri; E. Verdun; M. Bergui; M. Clerico; A. Ricci; L. Giordano; A. Rovera; E. Cartechini; G. Giuliani; E. Pucci; E. Montanari; L. Manneschi; L. Durelli
High-dose interferon-beta-1b (500 mcg every-other-day, subcutaneously) treatment in MS patients. Long-term evaluation and longitudinal comparison with preceding treatment with lower IFN beta dose
2004-01-01 P. Barbera; A. Pipieri; E. Verdun; M. Clerico; A. Ricci; M. A. Cucci; L. Giordano; E. Cartechini; G. Giuliani; E. Montanari; M. Bergui; L. Durelli
IFN beta-1b 500 mcg every-other-day, subcutaneously in MS patients. Tolerability, clinical and MRI results after one year of treatment
2005-01-01 M. Clerico; A. Pipaeri; P. Barbero; M. Bergui; F. Bruno; E. Verdun; L. Giordano; A. Ricci; E. Pucci; G. Giuliani; E. Cartechini; L. Manneschi; E. Montanari; E. Versino; A. Cucci; L. Durelli
IFN beta-1b in multiple sclerosis: comparing two different doses (the Optims Study).
2004-01-01 E. VERDUN; P. BARBERO; A. PIPIERI; A. RICCI; M. CLERICO; A. CUCCI; M. BERGUI; E. VERSINO; L. GIORDANO; M. ZAFFARONI; E. MONTANARI; G. GIULIANI; L. DURELLI; AND THE OPTIMS STUDY GROUP
Increasing dose of ifn beta 1b in ms patients: preliminary nab results from the optims study.
2003-01-01 VERDUN E; A. RICCI; P. BARBERO; M. CLERICO; A. PIPIERI; M. BERGUI; E. VERSINO; A. CUCCI; J.J. ZHONG; L. DURELLI; AND OPTIMS STUDY GROUP
Interferon beta-1b 500 mcg every-other-day in ms patients. Clinical and mri results
2005-01-01 P. BARBERO; A. PIPIERI; M. BERGUI; E. VERSINO; L. GIORDANO; M. CLERICO; A. RICCI; A. CUCCI; G. CONTESSA; M.L. GENESIA; E. PUCCI; E. CARTECHINI; L. MANNESCHI; I. PESCI; G; GIULIANI; E. MONTANARI; L. DURELLI
Interferon beta-1b 500 mcg every-other-day, subcutaneously in ms patients. Tolerability, clinical and mri results after one year of treatment
2005-01-01 M. CLERICO; A. PIPIERI; P. BARBERO; M. BERGUI; B. FERRERO; E. VERDUN; L. GIORDANO; A. RICCI; E. PUCCI; G. GIULIANI; E. CARTECHINI; L. MANNESCHI; E. MONTANARI; E. VERSINO; A. CUCCI; L. DURELLI
Interferon-beta-1b in multiple sclerosis: comparing two different doses (the OPTIMS Study)
2004-01-01 L. Durelli; E. Verdun; P. Barbero; A. Pipieri; A. Ricci; M. Clerico; M. A. Gucci; L. Giordano; M. Bergui; E. Versino
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
A 4-year multicenter follow-up of neutralizing anti-interferon antibodies in ms patients treated with high dose (375 mcg) interferon beta-1b | 2006 | A. TAVELLA; A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; B. FERRERO; A. ROVERA; G. CONTESSA; M. BERGUI; E. VERSINO; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP | |
A comparison of fully automatic and semi-manual contouring software for quantitative magnetic resonance imaging of lesion load in multiple sclerosis | 2005 | E. Festa; P. Barbero; A. Pipieri; M. Bergui; A. Boghi; G. Bradac; L. Giordano; L. Durelli | |
CEREBELLUM INTRINSIC CONNECTIVITY IN EATING DISORDERS | 2012 | F. D’AGATA, P. CAROPPO, L. LAVAGNINO, M. CAGLIO, A. SPALATRO, C. SETTANTA, M. CORIASCO, F. FERRIO, M. BERGUI, F. AMIANTO, S. FASSINO, L. PINESSI, P. MORTARA | |
Correlation of anti-interferon beta neutralising antobodies with clinical response and mri activity in the INCOMIN (independent comparison of interferon) trial. | 2003 | P. BARBERO; E. VERDUN; M. CLERICO; A. PIPIERI; A. RICCI; M. BERGUI; E. VERSINO; G. ANTONELLI; M. ZAFFARONI; A. GHEZZI; E. MONTANARI; L. DURELLI; AND INCOMIN STUDY GROUP | |
Differences in primary motor cortex identification by BOLD fMRI in patients with AVMs and gliomas | 2003 | M. Bergui; M. Bregu; A. Boghi; G. B. Bradac | |
Different pathogenesis of thalidomide neuropathy in multiple myeloma. | 2002 | G. ISOARDO; D. COCITO; P. BARBERO; M. BERGUI; P. CIARAMITARO; A. BERTOLA; M. BOCCADORO; B. BERGAMASCO; L. DURELLI | |
Different pathogenesis of thalidomide neuropathy in multiple myeloma. | 2002 | G. ISOARDO; D. COCITO; P. BARBERO; M. BERGUI; P. CIARAMITARO; A. BERTOLA; M. BOCCADORO; B. BERGAMASCO; L. DURELLI | |
Diffusion Tensor and Voxel Based Morphometry study in patients with amyotrophic lateral sclerosis | 2012 | Paola Caroppo, Federico D’Agata, Maria Federica Ferrio, Mario Coriasco, Andrea Calvo, Adriano Chiò, Dorico Righi, Paolo Mortara, Gianni Boris Bradac, Mauro Bergui | |
Every-other-day interferon beta-1b compared with once weekly interferon beta 1-a in ms. further analysis of treatment effect on mri activity and neutralizing antibodies (nabs) in the INCOMIN trial | 2004 | P. BARBERO; M. BERGUI; A. RICCI; E. VERSINO; A. PIPIERI; E. VERDUN; M. CLERICO; L. GIORDANO; A. CUCCI; L. DURELLI; INCOMIN STUDY GROUP | |
Every-other-day interferon beta-1b compared with once-weekly interferon beta-1a in MS. Further analysis of treatment effect on MR1 activity and neutralising antibodies (NAbs) in the INCOMIN Trial | 2004 | P. Barbero; A. Ricci; M. Bergui; E. Verdun; E. Versino; E. Montanari; A. Ghezzi; M. Zaffaroni; L. Durelli | |
Focal gray matter decrease in the cerebral pain network of migraine patients | 2006 | Valfre' W; Rainero I; Bergui M; Bradac GB; Gentile S; Ferrero M; Rubino E; Vaula G; Pinessi L | |
High dose interferon beta-1b in aggressive Multiple Sclerosis. tolerability, clinical and mri results after one year of treatment | 2006 | A. PIPIERI; P. BARBERO; M. BERGUI; E. VERSINO; M. CLERICO; L. GIORDANO; L. DELFICO; G. CONTESSA; A.M. CUCCI; E. VERDUN; I. PESCI; L. MANNESCHI; E. CARTECHINI; E. PUCCI; G. GIULIANI; E. MONTANARI; L. DURELLI | |
High-dose interferon beta-1b (500 mcg every-other-day, subcutaneously) treatment in RR MS patients. Safety and MRI results of 1-year follow-up | 2005 | P. Barbero; A. Pipieri; E. Verdun; M. Bergui; M. Clerico; A. Ricci; L. Giordano; A. Rovera; E. Cartechini; G. Giuliani; E. Pucci; E. Montanari; L. Manneschi; L. Durelli | |
High-dose interferon-beta-1b (500 mcg every-other-day, subcutaneously) treatment in MS patients. Long-term evaluation and longitudinal comparison with preceding treatment with lower IFN beta dose | 2004 | P. Barbera; A. Pipieri; E. Verdun; M. Clerico; A. Ricci; M. A. Cucci; L. Giordano; E. Cartechini; G. Giuliani; E. Montanari; M. Bergui; L. Durelli | |
IFN beta-1b 500 mcg every-other-day, subcutaneously in MS patients. Tolerability, clinical and MRI results after one year of treatment | 2005 | M. Clerico; A. Pipaeri; P. Barbero; M. Bergui; F. Bruno; E. Verdun; L. Giordano; A. Ricci; E. Pucci; G. Giuliani; E. Cartechini; L. Manneschi; E. Montanari; E. Versino; A. Cucci; L. Durelli | |
IFN beta-1b in multiple sclerosis: comparing two different doses (the Optims Study). | 2004 | E. VERDUN; P. BARBERO; A. PIPIERI; A. RICCI; M. CLERICO; A. CUCCI; M. BERGUI; E. VERSINO; L. GIORDANO; M. ZAFFARONI; E. MONTANARI; G. GIULIANI; L. DURELLI; AND THE OPTIMS STUDY GROUP | |
Increasing dose of ifn beta 1b in ms patients: preliminary nab results from the optims study. | 2003 | VERDUN E; A. RICCI; P. BARBERO; M. CLERICO; A. PIPIERI; M. BERGUI; E. VERSINO; A. CUCCI; J.J. ZHONG; L. DURELLI; AND OPTIMS STUDY GROUP | |
Interferon beta-1b 500 mcg every-other-day in ms patients. Clinical and mri results | 2005 | P. BARBERO; A. PIPIERI; M. BERGUI; E. VERSINO; L. GIORDANO; M. CLERICO; A. RICCI; A. CUCCI; G. CONTESSA; M.L. GENESIA; E. PUCCI; E. CARTECHINI; L. MANNESCHI; I. PESCI; G; GIULIANI; E. MONTANARI; L. DURELLI | |
Interferon beta-1b 500 mcg every-other-day, subcutaneously in ms patients. Tolerability, clinical and mri results after one year of treatment | 2005 | M. CLERICO; A. PIPIERI; P. BARBERO; M. BERGUI; B. FERRERO; E. VERDUN; L. GIORDANO; A. RICCI; E. PUCCI; G. GIULIANI; E. CARTECHINI; L. MANNESCHI; E. MONTANARI; E. VERSINO; A. CUCCI; L. DURELLI | |
Interferon-beta-1b in multiple sclerosis: comparing two different doses (the OPTIMS Study) | 2004 | L. Durelli; E. Verdun; P. Barbero; A. Pipieri; A. Ricci; M. Clerico; M. A. Gucci; L. Giordano; M. Bergui; E. Versino |